Steeve Provencher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1214236/publications.pdf

Version: 2024-02-01

94	7,067	66234	58464
papers	citations	42 h-index	82 g-index

95	95	95	6047
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1357-1360.	2.5	15
2	PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension. JACC Basic To Translational Science, 2022, 7, 384-403.	1.9	14
3	Pulmonary tumor thrombotic microangiopathy: A systematic review of the literature. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 20-27.	0.2	2
4	Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 614-627.	2.5	22
5	Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: A systematic review with meta-analysis. Pharmacological Research, 2021, 163, 105317.	3.1	15
6	Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. Thrombosis Research, 2021, 197, 24-32.	0.8	17
7	Pulmonary Disease, Pulmonary Hypertension and Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 141-153.	0.7	14
8	Implication of EZH2 in the Pro-Proliferative and Apoptosis-Resistant Phenotype of Pulmonary Artery Smooth Muscle Cells in PAH: A Transcriptomic and Proteomic Approach. International Journal of Molecular Sciences, 2021, 22, 2957.	1.8	9
9	17Î²-estradiol and estrogen receptor Î± protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. Journal of Clinical Investigation, 2021, 131, .	3.9	47
10	Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2021, 22, 2919.	1.8	9
11	Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms. European Respiratory Review, 2021, 30, 200284.	3.0	16
12	Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?. Cells, 2021, 10, 1473.	1.8	9
13	Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis. Vascular Pharmacology, 2021, 139, 106882.	1.0	33
14	Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension. Science Advances, 2021, 7, eabh3794.	4.7	16
15	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 148-157.	2.5	53
16	Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. American Journal of Physiology - Cell Physiology, 2020, 318, C1-C28.	2.1	26
17	Role of PKM2-PARP1/Inflammation/Oxidative DNA Damage Axis in the Pathogenesis of Right Ventricular Failure Associated with Pulmonary Arterial Hypertension. , 2020, , .		1
18	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest, 2020, 158, 2270-2274.	0.4	12

#	Article	IF	Citations
19	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation, 2020, 142, 1464-1484.	1.6	96
20	Pulmonary hypertension thresholds: time to lower further?. Lancet Respiratory Medicine,the, 2020, 8, 834-836.	5.2	4
21	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 214-225.	0.2	3
22	Long Non-Coding RNA H19 Promotes Right Ventricular Failure in PAH. , 2020, , .		1
23	Novel insights on the pulmonary vascular consequences of COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L277-L288.	1.3	125
24	Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension. Physiological Reports, 2020, 8, e14389.	0.7	7
25	Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension. Circulation Research, 2020, 126, 1723-1745.	2.0	83
26	Reply to Chen et al.: BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1313-1314.	2.5	0
27	DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 661-667.	1.0	23
28	PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 783-801.	1.1	16
29	Pulmonary vascular diseases. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, S2-S5.	0.2	0
30	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 177-198.	0.2	13
31	Extended Anticoagulation for VTE. Chest, 2019, 155, 1199-1216.	0.4	26
32	Inhibition of CHK 1 (Checkpoint Kinase 1) Elicits Therapeutic Effects in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1667-1681.	1.1	40
33	Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 910-920.	2.5	100
34	Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLoS ONE, 2019, 14, e0214134.	1.1	25
35	Long Non-Coding RNA H19 in the Pathogenesis of Right Ventricular Failure Associated with Pulmonary Arterial Hypertension -A Putative Novel Biomarker and Therapeutic Target-. , 2019, , .		0
36	Early Evidence for the Role of lncRNA TUG1 in Vascular Remodelling in Pulmonary Hypertension. Canadian Journal of Cardiology, 2019, 35, 1433-1434.	0.8	7

#	Article	IF	Citations
37	TAKling GDF-15 and skeletal muscle atrophy in pulmonary hypertension: are we there yet?. Thorax, 2019, 74, 103-105.	2.7	5
38	Outcomes following a negative computed tomography pulmonary angiography according to pulmonary embolism prevalence: a metaâ€analysis of the management outcome studies. Journal of Thrombosis and Haemostasis, 2018, 16, 1107-1120.	1.9	5
39	Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 90-103.	2.5	75
40	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension. Chest, 2018, 153, 1142-1152.	0.4	4
41	FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. Journal of Molecular Medicine, 2018, 96, 223-235.	1.7	62
42	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circulation Research, 2018, 122, 1021-1032.	2.0	111
43	Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 244-260.	2.5	52
44	Dual ET_A/ET_B blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-15.	0.8	19
45	Therapeutic Value of ASK1 Inhibition in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 284-286.	2.5	13
46	Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0204610.	1.1	13
47	Management of Severe Pulmonary Hypertensive Disease for Surgical and Nonsurgical Procedures. International Anesthesiology Clinics, 2018, 56, e28-e55.	0.3	4
48	Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. European Respiratory Review, 2018, 27, 180020.	3.0	3
49	Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1513-1523.	1.1	72
50	The cancer theory of pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 285-299.	0.8	154
51	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary Circulation, 2017, 7, 312-325.	0.8	37
52	Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	32
53	HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension. Scientific Reports, 2017, 7, 4546.	1.6	70
54	Clinical trial research in focus: improving drug development and trial design in pulmonary arterial hypertension. Lancet Respiratory Medicine,the, 2017, 5, 544-546.	5.2	2

#	Article	IF	Citations
55	MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 515-529.	2.5	134
56	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	2.5	113
57	DNA Damage and Pulmonary Hypertension. International Journal of Molecular Sciences, 2016, 17, 990.	1.8	85
58	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285.	2.5	88
59	Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 291-305.	5.2	190
60	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
61	Diagnostic yield of nonâ€guided flexible bronchoscopy for peripheral pulmonary neoplasia. Thoracic Cancer, 2015, 6, 517-523.	0.8	13
62	Impaired Skeletal Muscle Oxygenation and Exercise Tolerance in Pulmonary Hypertension. Medicine and Science in Sports and Exercise, 2015, 47, 2273-2282.	0.2	43
63	Near-fatal haemoptysis as presentation of a giant intralobar pulmonary sequestration. European Respiratory Review, 2015, 24, 155-156.	3.0	6
64	Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. Journal of Molecular Medicine, 2015, 93, 573-584.	1.7	53
65	Bromodomain-Containing Protein 4. Circulation Research, 2015, 117, 525-535.	2.0	143
66	Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation, 2015, 132, 932-943.	1.6	173
67	Potassium channels in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 1167-1177.	3.1	64
68	miR-223 reverses experimental pulmonary arterial hypertension. American Journal of Physiology - Cell Physiology, 2015, 309, C363-C372.	2.1	103
69	Current Treatment Approaches to Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2015, 31, 460-477.	0.8	24
70	A miR-208â€“Mef2 Axis Drives the Decompensation of Right Ventricular Function in Pulmonary Hypertension. Circulation Research, 2015, 116, 56-69.	2.0	101
71	Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension. PLoS ONE, 2015, 10, e0120657.	1.1	9
72	Alternatives to the Six-Minute Walk Test in Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e103626.	1.1	15

#	Article	IF	Citations
73	Role for DNA Damage Signaling in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 786-797.	1.6	211
74	Sirtuin 3 Deficiency Is Associated with Inhibited Mitochondrial Function and Pulmonary Arterial Hypertension in Rodents and Humans. Cell Metabolism, 2014, 20, 827-839.	7.2	170
75	Impaired Angiogenesis and Peripheral Muscle Microcirculation Loss Contribute to Exercise Intolerance in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 318-328.	2.5	99
76	miRNAs in PAH: biomarker, therapeutic target or both?. Drug Discovery Today, 2014, 19, 1264-1269.	3.2	25
77	Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life. Chest, 2014, 146, 686-708.	0.4	43
78	The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future. Expert Review of Respiratory Medicine, 2013, 7, 43-55.	1.0	14
79	Signal Transduction in the Development of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 278-293.	0.8	69
80	Anti-inflammatory and Immunosuppressive Agents in PAH. Handbook of Experimental Pharmacology, 2013, , 437-476.	0.9	24
81	Anti-inflammatory and Immunosuppressive Agents in PAH. Handbook of Experimental Pharmacology, 2013, 218, 437-476.	0.9	23
82	Signal Transducers and Activators of Transcription-3/Pim1 Axis Plays a Critical Role in the Pathogenesis of Human Pulmonary Arterial Hypertension. Circulation, 2011, 123, 1205-1215.	1.6	156
83	Role for miR-204 in human pulmonary arterial hypertension. Journal of Experimental Medicine, 2011, 208, 535-548.	4.2	487
84	Assessment of Daily Life Physical Activities in Pulmonary Arterial Hypertension. PLoS ONE, 2011, 6, e27993.	1.1	76
85	Effects of a Rehabilitation Program on Skeletal Muscle Function in Idiopathic Pulmonary Arterial Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention, 2010, 30, 319-323.	1.2	92
86	Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax, 2010, 65, 113-117.	2.7	150
87	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
88	Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults. Chest, 2009, 135, 760-768.	0.4	102
89	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S97-S107.	1.2	209
90	Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. European Respiratory Journal, 2008, 32, 393-398.	3.1	84

#	Article	IF	Citations
91	Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	0.6	277
92	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595.	1.0	272
93	Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. European Respiratory Journal, 2006, 27, 114-120.	3.1	108
94	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111.	1.6	1,040